Key result
High dose intravenous immunoglobulin infusion in a 76-year-old woman with myasthenia gravis was associated with the development of a non-ST elevation myocardial infarction.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
High-dose IVIg infusion may induce a hypercoagulable state leading to NSTEMI, highlighting the need for cardiac evaluation prior to treatment in patients with cardiovascular risks.
Intravenous immunoglobulins (IVIgs) are used for several indications, including autoimmune conditions. IVIg treatment is associated with several possible adverse reactions including induction of a hypercoagulable state. We report a 76-year-old woman treated with IVIg for myasthenia gravis, which developed chest pain and weakness following IVIg infusion. The symptoms were associated with ST segment depression in V4-6 and elevated troponin levels. The patient was diagnosed with non-ST elevation myocardial infarction (NSTEMI). The patient had no significant risk factor besides age and a cardiac perfusion scan was interpreted as normal (the patient refused to undergo cardiac catheterization). This case is compatible with IVIg-induced hypercoagulability resulting in NSTEMI. Cardiac evaluation should therefore be considered prior to initiation of IVIg treatment especially in patients with multiple cardiovascular risks.
No takes yet. Share an insight, caveat, or question.
Mizrahi et al. (2009) conducted a case report in Myasthenia gravis (n=1). Intravenous immunoglobulins (IVIgs) was evaluated on Non-ST elevation myocardial infarction (NSTEMI). High dose intravenous immunoglobulin infusion in a 76-year-old woman with myasthenia gravis was associated with the development of a non-ST elevation myocardial infarction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: